Gland Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

16.47

16.43

16.36

15.50

15.50

Share application money

1.67

0.08

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

7,935.16

7,141.72

5,886.93

3,630.74

2,846.62

Loan funds

Secured loans

3.82

3.93

3.93

4.07

4.96

Unsecured loans

-

-

-

-

-

Total

7,957.12

7,162.16

5,907.22

3,650.30

2,867.07

Uses of funds

Fixed assets

Gross block

2,292.88

2,080.30

1,430.30

1,347.62

1,219.58

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

722.33

578.11

476.07

379.52

290.83

Net block

1,570.55

1,502.19

954.23

968.10

928.74

Capital work-in-progress

177.22

190.75

337.81

188.47

123.16

Investments

8.16

163.03

0.55

-

-

Net current assets

Current assets, loans & advances

7,017.26

5,978.17

5,203.47

2,929.47

2,470.68

Less : current liabilities & provisions

816.06

671.98

588.84

435.74

655.51

Total net current assets

6,201.20

5,306.19

4,614.63

2,493.74

1,815.17

Miscellaneous expenses not written

-

-

-

-

-

Total

7,957.12

7,162.16

5,907.22

3,650.30

2,867.07

Notes:

Book value of unquoted investments

-

-

-

-

-

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

128.46

124.53

219.23

134.54

171.60

Number of equity sharesoutstanding (Lacs)

1647.01

1643.03

1635.93

1549.49

154.95